Exenatide and Pancreatitis: is the FAERS signal real?
Exenatide ↔ Pancreatitis
Exenatide is a GLP-1 receptor agonist; pancreatitis is a labelled risk (2,012 co-reports, PRR 15.8), and post-marketing reports prompted an FDA warning and label change. Whether the drug truly increases pancreatitis, or the excess reflects the underlying diabetes, obesity, and gallstone disease of the treated population, remains debated.
Regulatory basis: exenatide (Byetta) prescribing information — acute pancreatitis warning; FDA safety communications.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Latency of weeks to months is plausible |
| Strength | met | PRR 15.8, large |
| Consistency | partial | Reported across GLP-1 agonists |
| Specificity | not established | Cannot exclude cholelithiasis or alcohol |
| Biological gradient | not established | No established dose relationship |
| Plausibility | partial | Biologically debated |
| Coherence | not established | Meta-analyses are inconclusive |
| Experiment | n/a | Rare in trials |
| Analogy | partial | Debated analogy across incretin drugs |
This table is this page's own qualitative read of the literature cited above, not an automated or citation-gated assessment — see the note at the bottom of this page.
✓ Trial evidence found — Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes (NCT01652716)
| Adverse event | Experimental: Exenatide QWS Suspension (n=229) · Active Comparator: Exenatide BID (n=146) | |
|---|---|---|
| Pancreatitis | 2/229 | 0/146 |
Post-marketing signal terms appear in this trial's posted adverse-event tables; per-arm counts shown as affected/at-risk. View on ClinicalTrials.gov →